Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) EBIT (2020 - 2025)

Vivos Therapeutics' EBIT history spans 6 years, with the latest figure at -$6.4 million for Q4 2025.

  • Quarterly results put EBIT at -$6.4 million for Q4 2025, down 127.44% from a year ago — trailing twelve months through Dec 2025 was -$19.9 million (down 78.11% YoY), and the annual figure for FY2025 was -$19.9 million, down 78.09%.
  • EBIT for Q4 2025 was -$6.4 million at Vivos Therapeutics, down from -$4.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $8.7 million in Q4 2021 to a low of -$7.0 million in Q2 2022.
  • The 5-year median for EBIT is -$4.3 million (2023), against an average of -$3.9 million.
  • Peak annual rise in EBIT hit 239.41% in 2021, while the deepest fall reached 202.83% in 2021.
  • Year by year, EBIT stood at $8.7 million in 2021, then plummeted by 169.61% to -$6.1 million in 2022, then soared by 31.83% to -$4.1 million in 2023, then surged by 32.11% to -$2.8 million in 2024, then crashed by 127.44% to -$6.4 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$6.4 million, -$4.7 million, and -$4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.